BioSpace News Archive

BioCapital

Innovent’s MSCI ESG Rating Upgraded to A

Innovent Biologics, Inc. announces that the Company has been upgraded to ‘A’ according to Morgan Stanley Capital International’s latest ESG rating, ranking at the forefront of the biotechnology industry.

November 30, 2023
·
10 min read
Fresenius Medical Care completes change of legal form into a German stock corporation

Fresenius Medical Care announces the successful completion of its change of legal form from a partnership limited by shares into a German stock corporation as of November 30, 2023.

November 30, 2023
·
4 min read
Business

Peptone and The Institute of Oncology Research (IOR) Bellinzona Announce Collaborative Research Agreement

Peptone, a leader in translational biophysics and the design of novel therapeutics against intrinsically disordered proteins (IDPs), and The Institute of Oncology Research (IOR) today announced the commencement of a collaborative sponsored research agreement in prostate cancer.

November 30, 2023
·
2 min read
Genetown

Bicycle Therapeutics to Host R&D Day on December 14

Bicycle Therapeutics plc today announced that the company will host its first Research and Development (R&D) Day on Thursday, December 14.

November 30, 2023
·
2 min read
Business

Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update

Can-Fite BioPharma Ltd. announced financial results for the nine months ended September 30, 2023.

November 30, 2023
·
11 min read
Deals

AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio

AbbVie Inc. (NYSE: ABBV) and ImmunoGen, Inc. (NASDAQ: IMGN) today announced a definitive agreement under which AbbVie will acquire ImmunoGen, and its flagship cancer therapy ELAHERE® (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC).

November 30, 2023
·
13 min read
Drug Development

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003 in Major Depressive Disorder with 79% of Patients in Remission after Two 12mg Doses

Cybin Inc. today announced positive Phase 2 topline safety and efficacy data for CYB003, its proprietary deuterated psilocybin analog, being developed for the treatment of major depressive disorder (“MDD”).

November 30, 2023
·
10 min read
ObsEva Announces Application for a Moratorium to Facilitate Pivotal Deals

ObsEva SA announced that, following a comprehensive assessment of the company’s financial position, the Board of Directors has opted to seek a moratorium from the competent court in Geneva, Switzerland.

November 30, 2023
·
2 min read
Policy

Mithra receives guidance from the FDA for the DONESTA® NDA marketing authorization filing in the United States

Mithra announces that the US Food and Drug Administration has provided feedback regarding its new drug application marketing authorization filing in the United States.

November 30, 2023
·
7 min read
Fujirebio and Sysmex Expand CDMO Partnership into the Field of Neurodegenerative Diseases under Their Immunoassay Collaboration

Fujirebio Holdings, Inc. and Sysmex Corporation announced that they have entered into an agreement to expand their Contract Development and Manufacturing Organization partnership for Sysmex’s Automated Immunoassay System HISCL™-Series to include the field of neurodegenerative diseases, following the discussion based on the Basic Agreement on Business Collaboration in the field of immunoassay signed in October 2023*.

November 30, 2023
·
3 min read